• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    9/19/23 12:49:54 PM ET
    $AMPX
    $ARM
    $AUR
    $AVGR
    Industrial Machinery/Components
    Miscellaneous
    Semiconductors
    Technology
    Get the next $AMPX alert in real time by email

    Gainers

    Connexa Sports Technologies Inc. (NASDAQ:CNXA) shares jumped 124.2% to $0.1697 after falling 15% on Monday.

    Avinger, Inc. (NASDAQ:AVGR) gained 63.9% to $9.95, adding to outsized gains from Monday. On Monday, Avinger shares soared 46.8% after the company announced the commercial launch of its Tigereye ST image-guided CTO crossing device.

    Sezzle Inc. (NASDAQ:SEZL) shares climbed 46.6% to $18.95.

    PHAXIAM Therapeutics S.A. (NASDAQ:PHXM) rose 30% to $5.17.

    Elutia Inc. (NASDAQ:ELUT) shares gained 29.1% to $1.6006 after the company announced the sale of its Orthobiologics business unit to Berkeley Biologics LLC. Elutia announced $26 million private placement of 7,355,869 shares of common stock at $1.4275 per share.

    Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) surged 24.4% to $10.50. The FDA granted an investigational device exemption to initiate BACKBEAT Study evaluating Orchestra biomed's atrioventricular interval modulation therapy (BACKBEAT CNT) for hypertensive patients who are indicated for a dual-chamber cardiac pacemaker.

    Rackspace Technology, Inc. (NASDAQ:RXT) gained 20.2% to $1.78 after Raymond James upgraded the stock from Market Perform to Outperform and announced a $3.5 price target.

    Eos Energy Enterprises, Inc. (NASDAQ:EOSE) jumped 16.6% to $2.65.

    Neptune Wellness Solutions Inc. (NASDAQ:NEPT) rose 15% to $5.32 after falling 18% on Monday. Neptune Wellness announced intention to spinout Sprout Organics pursuant to the Morgan Stanley agreed to transaction.

    Solowin Holdings (NASDAQ:SWIN) climbed 14.8% to $2.3882.

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) gained 13.5% to $0.1048.

    Galera Therapeutics, Inc. (NASDAQ:GRTX) shares rose 13.2% to $0.2158. Galera scheduled a Type A meeting with the FDA to discuss next steps for its radiotherapy avasopasem.

    Lichen China Limited (NASDAQ:LICN) gained 11.6% to $1.15.

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) jumped 11.4% to $5.85.

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) gained 10% to $9.48.

    SelectQuote, Inc. (NYSE:SLQT) rose 9.6% to $1.2395. Selectquote COO William Grant, III reported purchase of 150,000 shares at an average price of $1.20 per share in Form 4 filing on Monday.

    Conduent Incorporated (NASDAQ:CNDT) gained 9.4% to $3.3703. Conduent and HealthEquity announced that they have entered into a definitive agreement to transfer BenefitWallet's Health Savings Account (HSA) portfolio to HealthEquity.

    Stem, Inc. (NYSE:STEM) gained 8.6% to $4.88. Stem expanded its India Center Of Excellence, aimed at fostering global growth, optimizing operations, and increasing customer value.

    Waldencast plc (NASDAQ:WALD) jumped 7.3% to $9.41.

    Semtech Corporation (NASDAQ:SMTC) gained 5% to $25.48. Semtech Director Paul V. Walsh Jr. acquired a total of 20,000 shares at an average price of $24.83.

    Losers

    Digital Transformation Opportunities Corp. (NASDAQ:DTOC) shares fell 34.5% to $19.00 after jumping 173% on Monday.

    Histogen Inc. (NASDAQ:HSTO) fell 32.9% to $0.4419 as the company reported board approval of complete liquidation and dissolution.

    Revance Therapeutics, Inc. (NASDAQ:RVNC) declined 26% to $12.27 after the company issued corporate update at Investor Day. Revance Therapeutics estimates total non-cash impairment charges from goodwill and other assets to be between an estimated $80 million and $100 million.

    Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares fell 26% to $0.2517 after declining 15% on Monday.

    Axcella Health Inc. (NASDAQ:AXLA) declined 24.5% to $11.32.

    MSP Recovery, Inc. (NASDAQ:LIFW) fell 23.8% to $0.0931 after dipping 35% on Monday.

    Terran Orbital Corporation (NYSE:LLAP) fell 19.4% to $1.1450 after the company priced its previously announced public offering of 23.2 million shares and warrants to purchase up to 23.2 million shares at a combined public offering price of $1.40 per share and accompanying warrant.

    60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) shares fell 18.9% to $0.90 after the company said it has withdrawn its COVID Phase IIB investigational new drug and announced plans to resubmit pending assessment of ability to meet FDA requirements.

    SCWorx Corp. (NASDAQ:WORX) fell 18.5% to $0.2130 after jumping 38% on Monday.

    T2 Biosystems, Inc. (NASDAQ:TTOO) fell 17.4% to $0.3796. T2 Biosystems shares gained over 65% on Monday after the FDA cleared the company's biothreat panel for commercial distribution.

    Equinox Gold Corp. (NYSE:EQX) shares slipped 17% to $4.3499 after the company reported a bought deal offering of convertible senior notes.

    Perspective Therapeutics, Inc. (NASDAQ:CATX) fell 15.2% to $0.2711 after jumping 56% on Monday.

    Ebix, Inc. (NASDAQ:EBIX) fell 14% to $11.27.

    Aurora Innovation, Inc. (NASDAQ:AUR) declined 13.6% to $3.0670. TD Cowen initiated coverage on Aurora Innovation with a Market Perform rating and announced a price target of $3.

    Amprius Technologies, Inc. (NYSE:AMPX) fell 11.2% to $4.4650. The company announced it will showcase its new silicon nanowire battery manufacturing line on Dec. 14.

    Cardlytics, Inc. (NASDAQ:CDLX) declined 10.9% to $14.56.

    NIO Inc. (NYSE:NIO) shares fell 10.4% to $9.23 after the company announced a proposed offering of $1 billion convertible senior notes.

    ProKidney Corp. (NASDAQ:PROK) dipped 10.3% to $5.77.

    Vasta Platform Limited (NASDAQ:VSTA) fell 9.9% to $3.5767.

    TuSimple Holdings Inc. (NASDAQ:TSP) fell 9.7% to $1.4526.

    Rocket Lab USA, Inc. (NASDAQ:RKLB) shares fell 9.2% to $4.5775 as the company's 41st mission succumbs to technical issues, prompting it to postpone its next mission and revise its third-quarter guidance.

    Carvana Co. (NYSE:CVNA) declined 8.5% to $47.53.

    Nanobiotix S.A. (NASDAQ:NBTX) fell 7.6% to $8.36.

    Arm Holdings plc (NASDAQ:ARM) fell 5% to $55.08 amid post-IPO volatility. Redburn Atlantic initiated coverage on the stock with a Neutral rating and a $50 price target.

    Now Read This: Wall Street's Most Accurate Analysts Say Buy These 3 Tech Stocks With Over 3% Dividend Yields

    Get the next $AMPX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMPX
    $ARM
    $AUR
    $AVGR

    CompanyDatePrice TargetRatingAnalyst
    NIO Inc.
    $NIO
    3/13/2026$6.80Hold → Buy
    HSBC Securities
    NIO Inc.
    $NIO
    3/11/2026$6.60Neutral → Buy
    Nomura
    Eos Energy Enterprises Inc.
    $EOSE
    2/27/2026$20.00Buy → Neutral
    Guggenheim
    Amprius Technologies Inc.
    $AMPX
    2/23/2026$17.00Buy
    Craig Hallum
    Perspective Therapeutics Inc.
    $CATX
    2/19/2026$16.00Overweight
    Piper Sandler
    Sezzle Inc.
    $SEZL
    2/12/2026$85.00Buy
    Needham
    Nanobiotix S.A.
    $NBTX
    2/6/2026Buy
    TD Cowen
    Arm Holdings plc
    $ARM
    2/5/2026Neutral → Buy
    New Street
    More analyst ratings

    $AMPX
    $ARM
    $AUR
    $AVGR
    SEC Filings

    View All

    SEC Form 424B5 filed by 60 Degrees Pharmaceuticals Inc.

    424B5 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/13/26 5:17:36 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/13/26 5:15:16 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Elutia Inc.

    10-K - ELUTIA INC. (0001708527) (Filer)

    3/13/26 4:11:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMPX
    $ARM
    $AUR
    $AVGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Semtech Launches 224Gbps IC Family for Linear Optics Era

    Purpose-built TIAs and drivers address LPO through NPO at 800G, 1.6T and higher densities as AI data centers move beyond DSP-based architectures Semtech Corporation (NASDAQ:SMTC), a leading provider of high-performance semiconductor, Internet of Things (IoT) systems and cloud connectivity service solutions, today announced a family of 224Gbps per lane Transimpedance Amplifiers (TIAs) and Mach-Zehnder Modulator (MZM) drivers for half retimed (LRO), LPO, XPO, Near-Packaged Optics (NPO) and Co-Packaged Optics (CPO) interconnect applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316364888/en/Semtech Launches 224Gbps I

    3/16/26 8:00:00 AM ET
    $SMTC
    Semiconductors
    Technology

    Carvana Board of Directors Approves 5 for 1 Forward Stock Split

    Carvana (NYSE:CVNA), the industry pioneer for buying and selling cars online, today announced that its Board of Directors approved a 5 for 1 split of its common stock. The split is designed to ensure that earning and buying whole shares of Carvana stock is within reach for all of its team members. "This is the first split in Carvana's history, and we believe it achieves the important goal of keeping our stock accessible to all of our team members," said Mark Jenkins, Chief Financial Officer of Carvana. "This decision follows significant stock appreciation as Carvana reached new all-time records for units and profitability while continuing to lead the industry in growth in 2025." Carvana

    3/13/26 9:05:00 AM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

    GAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on March 10, 2026 to three new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan (the "Plan"). The awards were approved by the independent Compensation Committee of the Board of Directors, and were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Under the Plan, the three new employees received an aggregate of 460,000 non-qualified stock options (the "Options"). The Options vest 25% on the first anniversary of the vesting commencement date, with th

    3/13/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMPX
    $ARM
    $AUR
    $AVGR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DAXXIFY issued to REVANCE THERAPEUTICS, INC.

    Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (SUPPL-2) with active ingredient DAXIBOTULINUMTOXINA-LANM has changed to 'Approval' on 08/11/2023. Application Category: BLA, Application Number: 761127, Application Classification:

    8/14/23 4:38:56 AM ET
    $RVNC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAXXIFY issued to REVANCE THERAPEUTICS, INC.

    Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (ORIG-1) with active ingredient daxibotulinumtoixnA-lanm has changed to 'Approval' on 09/07/2022. Application Category: BLA, Application Number: 761127, Application Classification:

    9/8/22 1:11:06 PM ET
    $RVNC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPX
    $ARM
    $AUR
    $AVGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Urban David bought $100,100 worth of shares (16,250 units at $6.16), increasing direct ownership by 35% to 62,471 units (SEC Form 4)

    4 - Eos Energy Enterprises, Inc. (0001805077) (Issuer)

    3/10/26 8:52:43 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Chief Executive Officer Mastrangelo Joe bought $157,262 worth of shares (23,900 units at $6.58), increasing direct ownership by 2% to 1,487,126 units (SEC Form 4)

    4 - Eos Energy Enterprises, Inc. (0001805077) (Issuer)

    3/5/26 8:48:21 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Director Dimitrief Alexander bought $90,600 worth of shares (15,000 units at $6.04), increasing direct ownership by 7% to 235,221 units (SEC Form 4)

    4 - Eos Energy Enterprises, Inc. (0001805077) (Issuer)

    3/4/26 8:56:17 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    $AMPX
    $ARM
    $AUR
    $AVGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NIO upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded NIO from Hold to Buy and set a new price target of $6.80

    3/13/26 8:42:10 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    NIO upgraded by Nomura with a new price target

    Nomura upgraded NIO from Neutral to Buy and set a new price target of $6.60

    3/11/26 8:29:36 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    Eos Energy downgraded by Guggenheim with a new price target

    Guggenheim downgraded Eos Energy from Buy to Neutral and set a new price target of $20.00

    2/27/26 8:28:11 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    $AMPX
    $ARM
    $AUR
    $AVGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Rodriguez Ricardo C. was granted 150,000 shares, increasing direct ownership by 75% to 350,000 units (SEC Form 4)

    4/A - Amprius Technologies, Inc. (0001899287) (Issuer)

    3/13/26 6:09:30 PM ET
    $AMPX
    Industrial Machinery/Components
    Miscellaneous

    Director Hsieh Wen Hsuan sold $7,620,033 worth of shares (413,146 units at $18.44) and exercised 270,251 shares at a strike of $2.61, decreasing direct ownership by 76% to 44,444 units (SEC Form 4)

    4 - Amprius Technologies, Inc. (0001899287) (Issuer)

    3/13/26 6:08:48 PM ET
    $AMPX
    Industrial Machinery/Components
    Miscellaneous

    Director Wehner David M. was granted 51,248 shares, increasing direct ownership by 67% to 127,472 units (SEC Form 4)

    4 - Aurora Innovation, Inc. (0001828108) (Issuer)

    3/13/26 4:27:19 PM ET
    $AUR
    EDP Services
    Technology

    $AMPX
    $ARM
    $AUR
    $AVGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by Eos Energy Enterprises Inc.

    SC 13D/A - Eos Energy Enterprises, Inc. (0001805077) (Subject)

    12/17/24 2:48:02 PM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $AMPX
    $ARM
    $AUR
    $AVGR
    Leadership Updates

    Live Leadership Updates

    View All

    Conduent Appoints Greta Van to Board of Directors

    Finance and Technology Leader Brings Decades of Experience in Audit, Controls, Risk, Compliance and Strategy Across Global Public Companies Conduent Incorporated (NASDAQ:CNDT), a global technology-driven business solutions and services company, today announced the appointment of Greta Van to its Board of Directors. Van brings more than two decades of progressive leadership experience spanning finance, audit, enterprise risk management, and strategic operations within global, publicly traded organizations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260306360053/en/Greta Van Van currently serves as Chief Audit Executive at J

    3/6/26 4:05:00 PM ET
    $CNDT
    Real Estate

    Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

    GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti will lead the commercialization for NXT-41x, Elutia's next-generation antibiotic-eluting biomatrix being developed to improve outcomes in plastic and reconstructive surgery. NXT-41x is Elutia's next-generation antibiotic-eluting biomatrix, built on the Company's validated drug-eluting platform. Elutia is applying that platform in plastic and reconstructive surgery, where breast reconstruction represents the largest and most underserved opportuni

    3/2/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

    GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and retention support consistent execution in regulated, innovation-driven industries. "Elutia isn't for everyone," said Dana Yoo, PhD, VP of Product Development. "The bar is high, and the work is hard. But

    2/18/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMPX
    $ARM
    $AUR
    $AVGR
    Financials

    Live finance-specific insights

    View All

    Waldencast Reports Q4 2025 and FY 2025 Financial Results

    FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing o

    3/13/26 6:50:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date

    LONDON, March 11, 2026 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open. The Company does not plan to host a conference call to discuss results given its ongoing strategic review. About Waldencast plc Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned

    3/11/26 4:05:00 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    NIO Inc. Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Quarterly Adjusted Profit From Operations (non-GAAP) Reached RMB1,251.3 Million (US$178.9 Million)i Quarterly Total Revenues Reached RMB34,650.2 Million (US$4,954.9 Million)iQuarterly Vehicle Deliveries Were 124,807 Units Full Year Total Revenues Reached RMB87,487.5 Million (US$12,510.5 Million) Full Year Vehicle Deliveries Were 326,028 Units SHANGHAI, China, March 10, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE:NIO, HKEX: 9866, SGX: NIO)) ("NIO" or the "Company"), a pioneer and a leading company in the global smart electric vehicle market, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Operating Highlights for the Fourth Quarter

    3/10/26 6:30:00 AM ET
    $NIO
    Auto Manufacturing
    Industrials